Lifeboat Foundation

Speculation about what order rejuvenation biotechnologies will arrive.

The first rejuvenation therapies to work well enough to merit the name will be based on the SENS vision: that aging is at root caused by a few classes of accumulated cell and tissue damage, and biotechnologies that either repair that damage or render it irrelevant will as a result produce rejuvenation. Until very recently, no medical technology could achieve this goal, and few research groups were even aiming for that outcome. We are in the midst of a grand transition, however, in which the research and development community is finally turning its attention to the causes of aging, understanding that this is the only way to effectively treat and cure age-related disease. Age-related diseases are age-related precisely because they are caused by the same processes of damage that cause aging: the only distinctions between aging and disease are the names given to various collections of symptoms. All of frailty, disease, weakness, pain, and suffering in aging is the result of accumulated damage at the level of cells and protein machinery inside those cells. Once the medical community becomes firmly set on the goal of repairing that damage, we’ll be well on the way to controlling and managing aging as a chronic condition — preventing it from causing harm to the patient by periodically repairing and removing its causes before they rise to the level of producing symptoms and dysfunction. The therapies of the future will be very different from the therapies of the past.

The full rejuvenation toolkit of the next few decades will consist of a range of different treatments, each targeting a different type of molecular damage in cells and tissues. In this post, I’ll take a look at the likely order of arrival of some of these therapies, based on what is presently going on in research, funding, and for-profit development. This is an update to a similar post written four years ago, now become somewhat dated given recent advances in the field. Circumstances change, and considerable progress has been made in some lines of research and development.

Continue reading “Predicting the Order of Arrival of the First Rejuvenation Therapies” »

Longevity a challenge or an opportunity?

This autumn, The Economist Events will bring global leaders from business, finance and health care together with policymakers to explore the opportunities of an ageing world.

Together they will discuss how best to adapt financial products and realign business and public policies in ways that will drive economic growth and mitigate problems that ageing societies could otherwise bring.

Continue reading “Ageing Societies 2016” »

New biomarkers for aging is good news for researchers!

“Given the high volume of data being generated in the life sciences, there is a huge need for tools that make sense of that data. As such, this new method will have widespread applications in unraveling the molecular basis of age-related diseases and in revealing biomarkers that can be used in research and in clinical settings. In addition, tools that help reduce the complexity of biology and identify important players in disease processes are vital not only to better understand the underlying mechanisms of age-related disease but also to facilitate a personalized medicine approach. The future of medicine is in targeting diseases in a more specific and personalized fashion to improve clinical outcomes, and tools like iPANDA are essential for this emerging paradigm,” said João Pedro de Magalhães, PhD, a trustee of the Biogerontology Research Foundation.

The algorithm, iPANDA, applies deep learning algorithms to complex gene expression data sets and signal pathway activation data for the purposes of analysis and integration, and their proof of concept article demonstrates that the system is capable of significantly reducing noise and dimensionality of transcriptomic data sets and of identifying patient-specific pathway signatures associated with breast cancer patients that characterize their response to Toxicol-based neoadjuvant therapy.

Continue reading “BGRF scientists publish seminal paper and announce project to develop biomarkers of aging” »

SENS makes official comment on the excellent news about Mitochondrial repair from UCLA and Caltech.

So the big news is progress has been made on Mitochondrial repair. Our resident expert at the SENS Research Foundation, Dr. Matthew O’Connor of the MitoSENS project had this to say about the exciting news:

“New work from UCLA and Caltech has shown that a genetic pathway can be harnessed to selectively remove mutant mitochondria from the muscles of fruit flies. This work from Kandul et al is exciting because it raises the possibility of someday finding a way to control this genetic pathway in such a way to selectively delete mutant mitochondria. Further they did it in live flies in a tissue (muscle) where we are especially concerned about the impact of mitochondrial DNA mutations. Our ability to selectively control genetic pathways in non-genetically engineered animals (such as humans) is, however, extremely limited so it may be a long time before any clinical benefits can be realized from this research.” — Dr. Matthew O’Connor SRF

Continue reading “Turning back the aging clock” »

Lifespan.io / Life Extension Advocacy Foundation

https://www.youtube.com/watch?v=QJSCYvFk6r4

A quick dash of Aubrey to remind us of the goal and the importance of research.

Aubrey believes ageing is a serious issue, not only because people die of old age, but because it causes suffering. He discusses the fact that many diseases including chronic cancer, are the result of ageing and that by tackling ageing of cells, we can address many of the issues associated with poor health. To find out more about Aubrey and the SENS Research Foundation visit: http://www.sens.org/

Check out my latest story for Newsweek: http://www.newsweek.com/dead-gone-forever-need-cryonics-policy-523030 #transhumanism #cryonics

The case of a 14-year-old UK girl whose body was preserved after death highlights the need for governments to take cryonics seriously.

Progress in real science is steady, follows proper methodology and respects engineering safety. We live in an amazing world where medical progress is advancing rapidly, sadly we also have those willing to jump the gun hawking unproven experimental therapies without sufficient data.

Unproven therapies and people jumping the gun to make a quick buck are a plague in the aging research field. Real science is slow and methodical but ultimately gets results that ensure safe therapies can be deployed in the healthcare arena. At Lifespan.io we are passionate about supporting the progress of science that is conducted properly.

“The life science community should embrace the discrediting of unproven therapies promoted without data for economic gain, and instead focus on the promise of research held to the highest standards.”

Continue reading “Reviving optimism for regenerative medicine” »

https://www.youtube.com/watch?v=3CT5IiLDnAY

There’s a quick line in here about how in the 70’s they took a look at the complexity of metabolism and decided no one would ever figure out how to solve aging. Might have been nice to have an Aubrey or a Parrish or an Andrews at the time to get started then.

Aubrey De Grey, Chief Science Officer for the SENS Research Foundation talks living forever young at London’s GIANT 2016 event. For more on Aubrey De Grey and gerontology: http://www.healthgauge.com/read/life-extension/